Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review
Authors:
- 27 March 2019
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 20 (4) , 483-491
Abstract
Biologic therapies pose a risk for opportunistic infections, especially for reactivating latent tuberculosis infection (LTBI).Keywords
This publication has 69 references indexed in Scilit:
- Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)British Journal of Dermatology, 2013
- Development of miliary tuberculosis related to anti‐tumor necrosis factor‐alpha inhibitor therapy for pustular psoriasisThe Journal of Dermatology, 2013
- Tuberculosis after anti-TNF therapy: a continuous learning processScandinavian Journal of Rheumatology, 2012
- Observational Studies: Cohort and Case-Control StudiesPlastic and Reconstructive Surgery, 2010
- Etanercept Therapy for Psoriasis in a Patient with Active Pulmonary TuberculosisAmerican Journal of Clinical Dermatology, 2010
- How tumour necrosis factor blockers interfere with tuberculosis immunityClinical and Experimental Immunology, 2010
- Interferon gamma release assays: principles and practiceEnfermedades Infecciosas y Microbiología Clínica, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Unusual presentation of tuberculosis in an infliximab-treated patient - which is the correct TB screening before starting a biologic?Dermatologic Therapy, 2010
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009